Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ibanez, B.
Right arrow Articles by Badimon, J. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ibanez, B.
Right arrow Articles by Badimon, J. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Pharmacology of thienopyridines: rationale for dual pathway inhibition

Borja Ibanez1,2, Gemma Vilahur1 and Juan J. Badimon1,*

1 Cardiovascular Biology Research Laboratory, the Zena and Michael A. Wiener Cardiovascular Institute, Box 1030, Mount Sinai School of Medicine, New York, NY 10029, USA
2 F. Conchita Rábago de Jiménez Díaz, Madrid, Spain

* Corresponding author. E-mail address: juan.badimon{at}mssm.edu

Atherothrombotic disease is the result of atherosclerosis progression, and its clinical manifestations, mostly secondary to atherosclerotic plaque disruption and subsequent thrombus formation. At the site of vascular lesions, platelets adhere to the exposed matrix proteins, prompting platelet activation, resulting in the secretion of multiple platelet agonists, mostly modulated by intracellular calcium release. Among them, ADP, thromboxane A2, thrombin, and others play a critical role in maintaining a ‘pro-platelet-activating’ environment. Aspirin has been considered the gold standard of antithrombotic therapy. Its antiplatelet activity is achieved mainly by inhibiting arachidonic acid pathway (blocking thromboxane A2 release from platelets). ADP binds to platelet P2Y12 receptor, although this receptor is important in platelet aggregation induced by other agonists. Thienopyridines (ticlopidine and clopidogrel) exert their antiplatelet activity by binding to the P2Y12 receptor, irreversibly modifying it. Oral clopidogrel loading dose of 300–600 mg clopidogrel produces significant inhibition of ADP-induced platelet aggregation 2 hours after administration, which becomes maximal after 6 hours. Both aspirin and clopidogrel are ‘selective platelet-receptor’ inhibitors, and therefore are weak and safe antiplatelet agents. The co-administration aspirin-clopidogrel results in enhancement of platelet inhibition, since the act via different platelet receptors. Current research is focused in reversible or more potent ADP antagonists.

Key Words: Acute coronary syndrome • ADP • Antiplatelet therapy • Aspirin • Clopidogrel • Thienopyridines • Thrombosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch SurgHome page
J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell
Antiplatelet Agents in the Perioperative Period
Arch Surg, January 1, 2009; 144(1): 69 - 76.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.